https://scholars.lib.ntu.edu.tw/handle/123456789/517080
標題: | Anti-influenza protective efficacy of a h6 virus-like particle in chickens | 作者: | Zhu, W.-Z. Wen, Y.-C. Lin, S.-Y. Chen, T.-C. HUI-WEN CHEN |
關鍵字: | Adjuvant; H6 avian influenza virus; Hemagglutinin; Matrix 1; Vaccine; Virus-like particles | 公開日期: | 2020 | 卷: | 8 | 期: | 3 | 起(迄)頁: | 1-13 | 來源出版物: | Vaccines | 摘要: | H6 avian influenza viruses (AIVs) have a worldwide distribution, and they pose a potential concern for public health. In Taiwan, H6 AIVs have circulated in domestic chickens for more than 40 years, and certain strains have crossed the species barrier to infect mammals. With the goal of containing the disease, there is a pressing need to develop a safe and effective vaccine for pandemic preparedness. In this study, we prepared a virus-like particle (VLP) that consisted of the hemagglutinin (HA) and matrix protein 1 (M1) derived from a H6 AIV as a vaccine antigen, and we examined the immunogenicity and protective efficacy when combined with an adjuvant in a chicken model. Full-length HA and M1 protein genes were cloned and expressed using a baculovirus expression system, and VLPs were purified from the supernatant of insect cell cultures. We performed nanoparticle-tracking analysis and transmission electron microscopy to validate that the particle structure and properties resembled the native virions. In animal experiments, specific-pathogen-free chickens that received the H6 VLPs in combination with an adjuvant showed superior H6N1 virus-specific serum IgG and hemagglutination-inhibition antibody responses, which lasted more than 112 days. Following the H6N1 viral challenge, the vaccinated chickens showed reduced viral replication in the lungs, kidneys and conjunctival/cloacal shedding. The antibodies induced in the chickens by the vaccine were able to cross-react with the H6N1 human isolate and drifted avian H6N1 isolates. In summary, the H6 VLP vaccine elicited superb immunogenicity in vivo, and the use of an adjuvant further enhanced the antiviral protective efficacy. This vaccine formulation could potentially be used to manage H6 influenza virus infections in chickens. ? 2020 by the authors. Licensee MDPI, Basel, Switzerland. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/517080 | DOI: | 10.3390/vaccines8030465 | SDG/關鍵字: | H6 virus particle vaccine; hemagglutinin; immunoglobulin G; influenza vaccine; matrix protein; matrix protein 1; nanoparticle; unclassified drug; animal cell; animal experiment; animal model; animal tissue; antibody response; antibody titer; antigen expression; Article; avian influenza virus; baculovirus expression system; chicken; controlled study; cross reaction; density gradient centrifugation; embryo; enzyme linked immunosorbent assay; fetal bovine serum; gene expression; H6 virus particle; hemagglutination inhibition test; hemagglutination test; humoral immunity; immunization; immunogenicity; immunogold staining; influenza; molecular cloning; molecular genetic phenomena and functions; nanoparticle tracking analysis; nonhuman; pharmacodynamic parameters; polyacrylamide gel electrophoresis; polymerase chain reaction; protective efficacy; reverse transcription; RNA extraction; Sf21 cell line; Sf9 cell line; transmission electron microscopy; virus particle; virus purification; virus replication; virus shedding; virus titration; Western blotting |
顯示於: | 獸醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。